Current methylation screening methods.
T. Wojdacz
DOI: https://doi.org/10.2217/epi.09.32
2009-12-03
Epigenomics
Abstract:DNA methylation is the covalent addition of a methyl group to the cytosines within a 5 -CpG-3 dinucleotide. More than 25 years ago, the methylation of the cytosines of the promoter sequences was shown to play an important role in the regulation of transcriptional activity of the genes [1]. Subsequently, it was suggested that methylation might contribute to tumorigenesis [2]. Today, methylation-dependent geneexpression aberrations have been demonstrated to contribute to all of the typical hallmarks of cancer [3]. At the same time, increasing evidence shows that aberrant methylation of cancerrelated genes could be used as a new target for effective early diagnosis and treatment of not only cancer but also many other diseases. Aberrant methylation of the cancer genes occurs in the early stages of carcinogenesis, and tumor DNA has long been shown to circulate in blood flow and other body fluids. That opens the possibility of early detection of the neoplastic process in simple, for example, blood-based, tests, once powerful and tumor-specific biomarkers have been discovered [4]. Furthermore, methylation changes, due to their nature, are potentially reversible, and therefore new compounds targeting the methylation changes can be used in the treatment of neoplastic disease [5]. The fundamental discoveries within both the fields of DNA methylation and genetics have occurred at the same time. However, for years, the field of methylation studies has lagged behind the developments within genetics due to the technological limitations and difficulties of methods for studies of methylation changes. The first technologies allowing for the investigation of methylation phenomenon relied on the endonucleases digesting the DNA, depending on the methylation status of the restriction site. The enzymatic digest was usually followed by Southern blotting. However, the fact that these methodologies require large amounts of DNA has been limiting their use, especially in cancer studies. Along with enzymatic approaches, at the beginning, field studies of total content of methylated cytosines in genomes were based on high-performance liquid chromatography and high-performance capillary chromatography techniques [6,7]. Those studies revealed the phenomena of the overall significant hypomethylation of cancer genomes. Currently, the protocols based on endonucleases and Southern blots are rarely used. However, methylationsensitive endonucleases digestion has been combined with real time (RT)-PCR technologies and integrated into genome-wide methylation study protocols (discussed below). The quantitative analysis of DNA methylation using RT-PCR (qAMP) technique is an example of the combination of methylation-sensitive endonuclease digestion and RT-PCR, where RT-PCR reveals a presence or absence of a digestion within the locus of interest [8]. During in vitro amplification of genomic DNA, all methylation information is lost. Therefore, in order to study methylation marks, the methylation pattern has to be preserved prior to the use of PCR. Revolutionary for the field was the use of sodium bisulfite, which allows to preserve methylation marks during PCR amplification. In principle, sodium bisulfite deaminates cytosines to uracil, while methylated cytosines remain unchanged. During the subsequent PCR amplification, retained 5-methylcytosines are amplified as cytosines, whereas thymine is incorporated at unmethylated cytosines sites. Current PCR-based methods for investigation of the methylation status of CpG sites within a locus if interest can be divided into two groups. One group of the technologies utilizes PCR for a